持田製薬(株)の貸借残高情報
主市場 | 業種 | 証券コード/EDINET | 英名称 |
---|
東証PRM | 医薬品 | 4534/E00947 | - |
公表日 | 公表 | 貸付残高 | 前週比 | 新規貸付成約高 | 前週比 | 借入残高 | 前週比 | 新規借入成約高 | 前週比 |
---|
2021/08/27 | 日証協 | 226,409株 | -1.96% | 214,066株 | +119.55% | 271,785株 | +13.9% | 71,610株 | +180.82% |
2021/08/20 | 日証協 | 230,938株 | -2.96% | 97,504株 | -3.39% | 238,614株 | -1.12% | 25,500株 | -22.02% |
2021/08/13 | 日証協 | 237,979株 | -12.46% | 100,929株 | +15.64% | 241,314株 | -9.22% | 32,700株 | -24.84% |
2021/08/06 | 日証協 | 271,850株 | +10.17% | 87,276株 | +27.12% | 265,814株 | +8.4% | 43,506株 | +51.06% |
2021/07/30 | 日証協 | 246,750株 | -3.48% | 68,656株 | +560.09% | 245,208株 | -4.78% | 28,800株 | +357.14% |
2021/07/21 | 日証協 | 255,651株 | -4.92% | 10,401株 | -60.36% | 257,508株 | -2.28% | 6,300株 | -77.5% |
2021/07/16 | 日証協 | 268,886株 | +0.34% | 26,236株 | -28.16% | 263,508株 | +5.01% | 28,000株 | -29.11% |
2021/07/09 | 日証協 | 267,978株 | +9.15% | 36,520株 | -70.83% | 250,930株 | +14.36% | 39,500株 | -69.44% |
2021/07/02 | 日証協 | 245,519株 | +78.64% | 125,181株 | +137.69% | 219,430株 | +81.57% | 129,239株 | +273.96% |
2021/06/25 | 日証協 | 137,438株 | -12.91% | 52,665株 | +22.19% | 120,851株 | -4.81% | 34,560株 | -8.01% |
2021/06/18 | 日証協 | 157,817株 | +8.37% | 43,100株 | +84.66% | 126,959株 | +41.55% | 37,568株 | +221.09% |
2021/06/11 | 日証協 | 145,627株 | -6.88% | 23,340株 | -29.06% | 89,691株 | -2.99% | 11,700株 | -33.98% |
2021/06/04 | 日証協 | 156,387株 | +1.35% | 32,900株 | -2.27% | 92,451株 | +10.01% | 17,723株 | -38.14% |
2021/05/28 | 日証協 | 154,308株 | +27.22% | 33,663株 | +6.11% | 84,042株 | +47.75% | 28,652株 | -2.36% |
2021/05/21 | 日証協 | 121,294株 | +0.86% | 31,726株 | -42.08% | 56,882株 | +69.38% | 29,346株 | +114.2% |
2021/05/14 | 日証協 | 120,264株 | +39.85% | 54,772株 | +289.01% | 33,582株 | +25.68% | 13,700株 | +1108.11% |
2021/05/07 | 日証協 | 85,992株 | +4.41% | 14,080株 | +20.05% | 26,721株 | +0.75% | 1,134株 | -29.12% |
2021/04/30 | 日証協 | 82,358株 | +0.24% | 11,728株 | -78.42% | 26,521株 | -0.77% | 1,600株 | -85.19% |
2021/04/23 | 日証協 | 82,164株 | +56.41% | 54,340株 | +124.67% | 26,726株 | -24.67% | 10,804株 | -46.62% |
※株式分割は考慮していませんのでご注意ください。
Page Top